Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Guidelines

TL;DR — Guideline bodies working from a largely shared evidence base set different numbers, and the disagreements are traceable to three things: what counts as a diagnosis versus a treatment trigger, which measurement method the trial targets were derived from, and how a body weighs population-level harm against individual-level benefit. The definitional split is the most visible: 2025 AHA/ACC and 2025 Hypertension Canada define hypertension at ≥130/80 mm Hg (Writing Committee 2025, PMID 40811516; Goupil 2025, PMID 40419299), while 2023 ESH, 2024 ESC, 2024 Chinese and 2021 WHO keep ≥140/90 (Mancia 2023, PMID 37345492; McEvoy 2024, PMID 39210715; Liu 2025, PMID 39762483; Al-Makki 2022, PMID 34775787). Applying the lower definition to US survey data raised hypertension prevalence from 31.9% to 45.6% but the proportion recommended drug therapy by only 1.9 percentage points (Muntner 2018, PMID 29133599) — the definitional gap is therefore mostly a labelling gap, not a prescribing gap. On treatment targets the convergence is real and recent: most current documents now aim below 130/80 mm Hg where tolerated. The synthesis of what these documents recommend lives here; the document catalogue with supersession chains lives in literature/guidelines/REGISTRY.md.

Where the major documents stand

Body / year Diagnostic threshold Treatment target Out-of-office measurement Notable position
2025 AHA/ACC (PMID 40811516; JACC PMID 40815242; Circulation PMID 40811497) ≥130/80 <130/80 for most Recommended for confirmation Retires and replaces the 2017 document; risk-informed treatment decisions in stage 1
2017 ACC/AHA (PMID 29133356) ≥130/80 <130/80 Recommended Introduced the lower definition; superseded 2025
2024 ESC (PMID 39210715) ≥140/90, with new "elevated BP" 120–139/70–89 category 120–129 systolic where tolerated Recommended Introduces a formal intermediate category rather than lowering the diagnostic threshold
2023 ESH (PMID 37345492) ≥140/90 <140/90 first, then toward 130/80 if tolerated 24-h ≥130/80, day ≥135/85, night ≥120/70 Endorsed by ISH and ERA; a 2024 clinical-practice condensation exists (Kreutz 2024, PMID 38914505)
2020 ISH — previous edition (PMID 32370572) ≥140/90 <140/90; <130/80 if feasible Where available Two-tier "essential" and "optimal" care standards for resource-stratified settings
2026 ISH global (PMID 42909506) ≥140/90 by standardised office BP; elevated BP 130–139/80–89 Essential <140/90; optimal <130/80, individualised for frailty and intolerance Standardised home monitoring is the main method under optimal care Tables 2–3 and treatment section retrieved in full on 2026-10-26; updates the 2020 edition
2026 ISH Africa, with PASCAR (PMID 42554264) Not in the indexed abstract Not in the indexed abstract — Simplified protocols for non-physician primary care. Numeric thresholds were not in the PubMed abstract; Europe PMC had no full text on 2026-10-12
2021 WHO (PMID 34775787) ≥140/90 <140/90; <130/80 in established CVD or high risk Encouraged Treatment-focused; explicitly addresses task-shifting and single-pill combinations
2025 Hypertension Canada (PMID 40419299) ≥130/80 <130 systolic Standardised measurement mandated Built on the WHO HEARTS framework; 9 recommendations, primary-care authored
2024 Chinese (PMID 39762483) ≥140/90 <130/80 for most if tolerated Ambulatory/home as diagnostic alternatives; validated wearables for screening Salt substitutes and a Chinese heart-healthy diet recommended; sleep and mental health added to lifestyle
2019 JSH (PMID 31375757) ≥140/90 Age- and comorbidity-stratified Strong home-monitoring tradition (Imai 2003, PMID 14621179) Home blood pressure prioritised over office where they conflict (Kario 2019, PMID 31760704; Hoshide 2020, PMID 31891452)
2021 KDIGO (CKD) (PMID 33637192) — <120 systolic by standardised office measurement Dedicated measurement chapter The most aggressive target in any guideline, and the most contested (Carriazo 2022, PMID 35498896)
2025 Endocrine Society (primary aldosteronism) (PMID 40658480) — — — Suggests screening all people with hypertension for primary aldosteronism
2021 USPSTF (PMID 33904861) — — Required before starting treatment Grade A: screen all adults ≥18 with office measurement; confirm out of office (Anstey 2021, PMID 33904916)
NICE NG136 (UK; updated 2026) Clinic ≥140/90 and daytime ABPM/HBPM ≥135/85 Clinic <140/90 if age <80; <150/90 if age ≥80; corresponding ABPM/HBPM <135/85 and <145/85 Required for diagnostic confirmation Primary recommendations retrieved at audit: NICE — “Hypertension in adults: diagnosis and management”, https://www.nice.org.uk/guidance/ng136/chapter/recommendations, accessed 2026-09-01; indexed summaries (Jones 2020, PMID 32001477; McCormack 2012, PMID 22429432; NG136 record PMID 31577399)

Newly indexed guidance, 2026-10-26. The Taiwan Hypertension Society has published dedicated guidance for older adults (Cheng 2026, PMID 42926177), and KDOQI a commentary on the 2025 AHA/ACC guideline in non-dialysis CKD (Chang 2026, PMID 42907045). Both are catalogued in the registry; their full texts were not retrieved, so their detailed recommendations are not incorporated into this comparison.

The four substantive disagreements

1. Where diagnosis begins. The 130/80 versus 140/90 split is about labelling, not mostly about drugs: applying 2017 ACC/AHA criteria to NHANES 2011–2014 raised prevalence 13.7 percentage points while raising the drug-recommended proportion 1.9 points, because the newly labelled group is largely recommended lifestyle intervention alone; among those already on treatment, however, the proportion above goal rose from 39.0% to 53.4% (Muntner 2018, PMID 29133599). The counter-argument is that labelling has costs — anxiety, insurance and employment consequences, and therapeutic inertia when a large low-risk group is nominally "uncontrolled". The ESC's response was to create an intermediate "elevated BP" category rather than move the diagnostic line (McEvoy 2024, PMID 39210715). Moving from the 2017 to the 2025 US document does not, on NHANES, relabel a large new treatment population inside stage 1: among 1,926 adults aged 30–79 with stage 1 hypertension (weighted 32.57 million; 2015–March 2020), 59.59% (19.41 million) were untreated, and the abstract reports that 13.84% (95% CI 7.06–20.63%) of untreated adults eligible under the PREVENT threshold (0.42 million) became newly eligible for drug therapy. Those two figures are quoted as printed: 13.84% of the 19.41 million untreated adults is not 0.42 million, and this page does not choose between them. The authors' conclusion is that the two guidelines were largely concordant in this group (Jian 2026, PMID 42858041).

2. How low to treat. Documents have converged toward <130/80 mm Hg, but from different reasoning. The 2024 ESC specifies 120–129 systolic where tolerated — closer to SPRINT's arm than to a conventional target — while ESH prefers a staged approach beginning at <140/90 (McEvoy 2024, PMID 39210715; Mancia 2023, PMID 37345492). The BPLTTC age-stratified analysis explicitly recommends removing age-based thresholds (BPLTTC 2021, PMID 34461040), which no guideline has fully done. See blood-pressure targets.

3. Which measurement. SPRINT's target was attained by unattended automated office measurement, which reads lower than conventional attended office readings by a heterogeneous amount (Andreadis 2019, PMID 31290085). KDIGO's <120 recommendation is explicit that it applies to standardised office readings and devotes a chapter to measurement precisely for this reason (KDIGO 2021, PMID 33637192; Cheung 2021, PMID 33637203). NICE goes furthest in the opposite direction, requiring ambulatory or home confirmation before a diagnosis is made at all (Jones 2020, PMID 32001477). The 2024 Chinese guidelines are the first major document to admit validated smart wearables for screening and monitoring (Liu 2025, PMID 39762483) — a position not shared by bodies that have reviewed cuffless validation evidence (Stergiou 2023, PMID 37303198).

4. Resource stratification. ISH's essential-versus-optimal two-tier structure and WHO's treatment-focused document are written for settings where the constraint is delivery, not knowledge (Unger 2020, PMID 32370572; Al-Makki 2022, PMID 34775787). The 2026 ISH guidelines for Africa, written with the Pan African Society of Cardiology, argue that international models do not fit the continent's clinical, cultural and resource conditions, and describe simplified protocols for the non-physician workers who deliver most primary care, plus opportunistic screening in schools, markets and places of worship (Doku 2026, PMID 42554264). The indexed abstract does not state numeric thresholds, and Europe PMC had no full text on 2026-10-12, so none are inferred here. Applying the 2025 AHA/ACC criteria, rather than JNC 7, to a Lagos survey of 3,030 people aged 17–92 labelled 2,788 (92.0%) as hypertensive and raised pharmacotherapy eligibility by 17.2% in males and 18.0% in females; among 242 treated participants, target control was 19.4% by JNC 7 and 10.7% by AHA/ACC 2025 (Adegoke 2026, PMID 42688995). That analysis excluded kidney-disease and PREVENT-tool eligibility, so it is not the full 2025 algorithm, and it is one city survey, not a national prevalence. A 2026 comparison of HEARTS 2.0 with the 2025 AHA/ACC guideline found concordance on measurement, risk-based care, early single-pill combinations, rapid intensification and team-based care, and named the remaining differences as the diagnostic threshold, targets below 130/80 mm Hg, and emerging cardiometabolic drugs (DiPette 2026, PMID 42756877). Economic modelling in 24 low- and middle-income countries found that in the lowest-income settings, net economic benefit was maximised by treating from systolic ≥160 mm Hg rather than ≥140 (Hutchinson 2024, PMID 38626959) — a conclusion no clinical guideline states, and a real tension between clinical and public-health optimisation. SciELO returned HTTP 403 on 2026-10-12, and a LILACS search was not completed, so this section does not speak to Latin American regional literature.

Where guidelines agree

  • Out-of-office measurement should confirm diagnosis before treatment is started (USPSTF 2021, PMID 33904861; NICE via Jones 2020, PMID 32001477; most others).
  • Thiazide-type diuretics, ACE inhibitors or ARBs, and calcium channel blockers are first-line; β-blockers require a compelling indication (Wright 2018, PMID 29667175; Wiysonge 2017, PMID 28107561).
  • Combination therapy, preferably as a single pill, should be started early in most people rather than after sequential monotherapy failure (Webster 2018, PMID 30120478; Chow 2021, PMID 34469767).
  • Lifestyle measures are first-line and continue alongside drugs — the ISH lifestyle position paper, endorsed by the World Hypertension League and ESH, is the fullest statement (Charchar 2024, PMID 37712135).
  • Spironolactone is the fourth-line agent of choice in resistant hypertension (Williams 2015, PMID 26414968). A 2026 ACC Expert Consensus Decision Pathway on resistant hypertension has been published (Davis 2026, PMID 42831847). PubMed types it as a review, the record has no abstract, and an Europe PMC title search on 2026-10-12 returned no record, so its recommendations are catalogued and not summarised.
  • In acute stroke, guidelines converge closely: no routine lowering in acute ischaemic stroke unless systolic ≥220 or diastolic ≥120 (110) mm Hg, then ~15% within 24 hours; <185/110 before thrombolysis or thrombectomy and <180/105 for 24 hours after; rapid but titrated reduction toward ~140 mm Hg in intracerebral haemorrhage; <130/80 long-term after either (Koga 2026, PMID 41514030). See stroke.

Where guidance has not caught up with the evidence

  • Primary aldosteronism screening. The 2025 Endocrine Society guideline suggests screening every person with hypertension (Adler 2025, PMID 40658480), on prevalence data showing biochemically overt disease in 11.3–22.0% across the pressure spectrum (Brown 2020, PMID 32449886). The general-guideline position is more varied than that earlier absence claim implied: a full-text comparative review describes broader screening in the 2024 ESC and 2025 AHA/ACC documents, with different eligible populations and recommendation strengths (Owei 2026, PMID 41645899). The 2026 ISH global guideline still recommends secondary-cause investigation in selected cases (Stergiou 2026, PMID 42909506). See secondary hypertension.
  • Diabetes targets. Several documents still reflect ACCORD-BP-era caution, which ESPRIT and BPROAD have superseded (Liu 2024, PMID 38945140; Bi 2025, PMID 39555827). A Cochrane review of this question is in protocol only and has not reported (Larvie 2026, PMID 42788405); see blood-pressure targets.
  • Age thresholds. BPLTTC's recommendation to remove age-based thresholds has not been implemented (BPLTTC 2021, PMID 34461040).
  • Inpatient blood pressure. No guideline sets an inpatient target; three large observational studies suggest current practice is harmful (Anderson 2023, PMID 37252732; Rastogi 2021, PMID 33369614; Canales 2025, PMID 39585709). See hypertensive emergencies.
  • Protocol availability. Standardised treatment protocols — the operational core of every successful implementation programme — are unevenly available worldwide and imperfectly aligned with the guidelines they are meant to implement (Satheesh 2024, PMID 38108382).

Reading a guideline critically

Three questions separate substantive disagreement from apparent disagreement: (1) Is the number a diagnostic label or a treatment trigger? (2) By what measurement method was it derived, and does the reader use that method? (3) Was the recommendation set for an individual clinician or for a health system with a fixed budget? Most cross-guideline "conflicts" resolve once these are separated. The genuine residue — how low to treat frail people, whether to screen everyone for primary aldosteronism, whether wearables may diagnose — is small and identifiable.

Open questions

  • Does the lower diagnostic threshold produce net benefit once labelling harms are counted? The 2026-09-01 PubMed and ClinicalTrials.gov searches located modelling and diagnostic-accuracy studies but no trial randomising a hypertension definition and measuring clinical outcomes (Muntner 2018, PMID 29133599).
  • Which guideline body's approach to the measurement-method problem is right — mandate the trial method (KDIGO), mandate out-of-office confirmation (NICE), or leave it implicit (most)? (KDIGO 2021, PMID 33637192; Jones 2020, PMID 32001477)
  • Should validated wearables be admitted for screening, as the 2024 Chinese guidelines do, when the validation literature is heterogeneous and includes retracted reports? (Liu 2025, PMID 39762483; Stergiou 2023, PMID 37303198)
  • Can a single global guideline serve settings whose economically optimal treatment thresholds differ by 20 mm Hg? (Hutchinson 2024, PMID 38626959; Unger 2020, PMID 32370572)
  • How long should it take a guideline to absorb a trial that reverses a major recommendation — and what is the mechanism for doing it faster than the next full revision cycle? (Bi 2025, PMID 39555827; Adler 2025, PMID 40658480)

References

  1. Writing Committee Members. 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. Hypertension. 2025;82:e212-e316. PMID 40811516
  2. Jones DW, et al. 2025 AHA/ACC Guideline for High Blood Pressure in Adults. J Am Coll Cardiol. 2025;86:1567-1678. PMID 40815242
  3. Writing Committee Members. 2025 AHA/ACC Guideline for High Blood Pressure in Adults. Circulation. 2025;152:e114-e218. PMID 40811497
  4. Whelton PK, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71:e13-e115. PMID 29133356
  5. Carey RM, et al. Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Synopsis of the 2017 ACC/AHA Guideline. Ann Intern Med. 2018;168:351-358. PMID 29357392
  6. Reboussin DM, et al. Systematic Review for the 2017 ACC/AHA High Blood Pressure Guideline. Hypertension. 2018;71:e116-e135. PMID 29133355
  7. McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912-4018. PMID 39210715
  8. Mancia G, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41:1874-2071. PMID 37345492
  9. Kreutz R, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1-15. PMID 38914505
  10. Sarafidis P, et al. A European Renal Association synopsis for nephrology practice of the 2023 ESH Guidelines. Nephrol Dial Transplant. 2024;39:929-943. PMID 38365947
  11. Unger T, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334-1357. PMID 32370572
  12. Al-Makki A, et al. Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. Hypertension. 2022;79:293-301. PMID 34775787
  13. Campbell NRC, et al. 2021 WHO guideline on pharmacological treatment of hypertension: Policy implications for the region of the Americas. Lancet Reg Health Am. 2022;9. PMID 35711684
  14. Goupil R, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197:E549-E564. PMID 40419299
  15. Rabi DM, et al. Hypertension Canada's 2020 Comprehensive Guidelines. Can J Cardiol. 2020;36:596-624. PMID 32389335
  16. Liu J. Highlights of the 2024 Chinese hypertension guidelines. Hypertens Res. 2025;48:1048-1053. PMID 39762483
  17. Umemura S, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235-1481. PMID 31375757
  18. Kario K. Key Points of the 2019 Japanese Society of Hypertension Guidelines. Korean Circ J. 2019;49:1123-1135. PMID 31760704
  19. Hoshide S, et al. Highlights of the 2019 JSH Guidelines and perspectives on Asian hypertensive patients. J Clin Hypertens. 2020;22:369-377. PMID 31891452
  20. Imai Y, et al. Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res. 2003;26:771-82. PMID 14621179
  21. KDIGO Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in CKD. Kidney Int. 2021;99:S1-S87. PMID 33637192
  22. Cheung AK, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline. Kidney Int. 2021;99:559-569. PMID 33637203
  23. Carriazo S, et al. Blood pressure targets in CKD 2021: the never-ending guidelines debacle. Clin Kidney J. 2022;15:845-851. PMID 35498896
  24. Adler GK, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110:2453-2495. PMID 40658480
  25. US Preventive Services Task Force. Screening for Hypertension in Adults: USPSTF Reaffirmation Recommendation Statement. JAMA. 2021;325:1650-1656. PMID 33904861
  26. Anstey DE, et al. USPSTF Recommendation Statement on Hypertension Screening in Adults-Where Do We Go From Here? JAMA Netw Open. 2021;4:e214203. PMID 33904916
  27. Jones NR, et al. Diagnosis and management of hypertension in adults: NICE guideline update 2019. Br J Gen Pract. 2020;70:90-91. PMID 32001477
  28. McCormack T, et al. Management of hypertension in adults in primary care: NICE guideline. Br J Gen Pract. 2012;62:163-4. PMID 22429432
  29. Flynn JT, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140. PMID 28827377
  30. Charchar FJ, et al. Lifestyle management of hypertension: International Society of Hypertension position paper. J Hypertens. 2024;42:23-49. PMID 37712135
  31. Muntner P, et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation. 2018;137:109-118. PMID 29133599
  32. Blood Pressure Lowering Treatment Trialists' Collaboration. Age-stratified and blood-pressure-stratified effects. Lancet. 2021;398:1053-1064. PMID 34461040
  33. Andreadis EA, et al. Attended Versus Unattended Automated Office Blood Pressure. High Blood Press Cardiovasc Prev. 2019;26:293-303. PMID 31290085
  34. Stergiou GS, et al. ESH recommendations for the validation of cuffless blood pressure measuring devices. J Hypertens. 2023;41:2074-2087. PMID 37303198
  35. Hutchinson B, et al. Scaling hypertension treatment in 24 low-income and middle-income countries. BMJ Open. 2024;14:e071036. PMID 38626959
  36. Wright JM, et al. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018;4:CD001841. PMID 29667175
  37. Wiysonge CS, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2017;1:CD002003. PMID 28107561
  38. Webster R, et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care (TRIUMPH). JAMA. 2018;320:566-579. PMID 30120478
  39. Chow CK, et al. Initial treatment with a single pill containing quadruple combination of quarter doses (QUARTET). Lancet. 2021;398:1043-1052. PMID 34469767
  40. Williams B, et al. Spironolactone versus placebo, bisoprolol, and doxazosin (PATHWAY-2). Lancet. 2015;386:2059-2068. PMID 26414968
  41. Koga M. Blood pressure management in stroke: comparative review of the 2025 AHA/ACC, 2024 ESC, 2023 ESH, and 2025 JSH guidelines. Hypertens Res. 2026;49:984-987. PMID 41514030
  42. Brown JM, et al. The Unrecognized Prevalence of Primary Aldosteronism. Ann Intern Med. 2020;173:10-20. PMID 32449886
  43. Liu J, et al. Lowering systolic blood pressure to less than 120 mm Hg (ESPRIT). Lancet. 2024;404:245-255. PMID 38945140
  44. Bi Y, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes (BPROAD). N Engl J Med. 2025;392:1155-1167. PMID 39555827
  45. Anderson TS, et al. Clinical Outcomes of Intensive Inpatient Blood Pressure Management in Hospitalized Older Adults. JAMA Intern Med. 2023;183:715-723. PMID 37252732
  46. Rastogi R, et al. Treatment and Outcomes of Inpatient Hypertension Among Adults With Noncardiac Admissions. JAMA Intern Med. 2021;181:345-352. PMID 33369614
  47. Canales MT, et al. As-Needed Blood Pressure Medication and Adverse Outcomes in VA Hospitals. JAMA Intern Med. 2025;185:52-60. PMID 39585709
  48. Satheesh G, et al. Standardized treatment protocols for hypertension: global availability, characteristics, and alignment. J Hypertens. 2024;42:902-908. PMID 38108382
  49. Touyz RM. Hypertension Guidelines: Effect of Blood Pressure Targets. Can J Cardiol. 2019;35:564-569. PMID 31030859
  50. Moick S, et al. WHO Guideline for the Pharmacological Treatment of Hypertension in Adults. Gesundheitswesen. 2023;85:139-142. PMID 36791691
  51. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline NG136. 2026. PMID 31577399. The guidance page, retrieved 2026-10-12, shows published 28 August 2019 and last updated 26 February 2026 (NICE — "Hypertension in adults: diagnosis and management", https://www.nice.org.uk/guidance/ng136, accessed 2026-10-12).
  52. Doku A, et al. 2026 ISH guidelines for the management of hypertension in Africa. J Hypertens. 2026;44:1732-1760. PMID 42554264
  53. Jian Q, et al. Guideline-Directed Treatment Eligibility and Burden of Untreated Stage-1 Hypertension Under the 2025 American College of Cardiology/American Heart Association Hypertension Guideline. J Am Heart Assoc. 2026:e049525. PMID 42858041
  54. Adegoke O, et al. Implications of the 2025 AHA/ACC hypertension guideline on hypertension prevalence, treatment eligibility and blood pressure control in Nigeria. BMJ Public Health. 2026;4:e005006. PMID 42688995
  55. DiPette DJ, et al. 2025 AHA/ACC blood pressure guideline and HEARTS 2.0: implications for the future evolution of integrated cardiovascular-kidney-metabolic care in the Americas. Rev Panam Salud Publica. 2026;50:e85. PMID 42756877
  56. Davis LL, et al. Optimizing Blood Pressure Care in Patients With Resistant Hypertension: 2026 ACC Expert Consensus Decision Pathway. J Am Coll Cardiol. 2026. PMID 42831847
  57. Larvie DY, et al. Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev. 2026;9:CD016392. PMID 42788405
  58. Stergiou GS, et al. 2026 International Society of Hypertension Global Hypertension Practice Guidelines. J Hypertens. 2026. PMID 42909506
  59. Cheng HM, et al. 2026 THS guidelines for the management of hypertension in older adults: Developed by the task force on the management of hypertension of the Taiwan Hypertension Society (THS) and endorsed by the Taiwan Society of Cardiology (TSOC), Taiwan Association of Gerontology and Geriatrics (TAGG), and Taiwan Society of Family Medicine (TSFM). J Formos Med Assoc. 2026. PMID 42926177
  60. Chang TI, et al. KDOQI Commentary on the 2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Am J Kidney Dis. 2026;88:645-681. PMID 42907045
  61. Owei L, et al. Broadening Primary Aldosteronism Screening: Alignment Across Contemporary Guidelines. Hypertension. 2026;83:e26228. PMID 41645899